Tag Archives: srpt

KaloBios, Valeant Lead Week’s 5 Top Drug Stock Gainers

Medical spending tends to rise steadily, but drug stocks can see huge swings as clinical trials, FDA reviews and other news buoy or torpedo the outlook. This week’s 5 big drug winners* rallied for diverse reasons. KaloBios Pharmaceuticals (KBIO) skyrocketed as new buyers stepped in before liquidation. Valeant Pharmaceuticals (VRX) rebounded after a huge sell-off. Sarepta Therapeutics (SRPT) benefited from a rival’s bad news. Voyager Therapeutics

Sarepta Stock Soars On New Muscular-Dystrophy Data

Biotech Sarepta Therapeutics (SRPT) revealed more data from its latest trial of muscular-dystrophy drug eteplirsen Thursday morning, sending the stock up sharply in early trading. Sarepta said that after three years on eteplirsen, the subjects of its phase-two study of Duchenne muscular dystrophy (DMD) in a six-minute walk test showed an advantage of 151 meters compared with the control group. The control group here was somewhat non-standard,

Sarepta Upgraded On Promising Muscular-Dystrophy Drug

Biotech Sarepta Therapeutics (SRPT) got an upgrade and a price target increase Wednesday, a day after it said the FDA had finally accepted its filing for muscular-dystrophy drug eteplirsen. Late Tuesday, Sarepta said the agency had granted eteplirsen priority review and set its deadline for making an approval decision at Feb. 26. The drug treats cases of Duchenne muscular dystrophy (DMD) associated with a genetic mutation of exon 51, which